Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life

Status:	Completed
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	6/22/2018
Start Date:	August 2010
End Date:	June 2018

Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life

The investigators are doing this study to learn about the quality of life patients have at
the end of treatment. Some patients' cancers are related to human papilloma virus or HPV;
others are not. HPV is a virus that can be sexually transmitted and is known to cause some
types of cancers. If your throat cancer was related to HPV, your doctor can discuss this with
you in detail. The investigators want to see if there are differences in quality of life
between patients whose cancers are caused by HPV and those who cancers are not caused by HPV.
Throat cancers caused by HPV behave differently than throat cancers not caused by HPV. The
investigators believe that patients with these two different types of throat cancer will also
have different experiences after completing therapy. The investigators would like to
understand what those differences are. The long-term goal of this study is to see what
symptoms most patients have. The investigators can then try to treat them earlier, and
hopefully, improve the symptoms. The investigators will also be able to plan more research to
improve treatment for symptoms following treatment for cancer of the mouth and throat.

Inclusion Criteria:

- 18 years of age or older

- Diagnosis of squamous cell carcinoma of the oropharynx confirmed by the pathology
department at MSKCC

- Completed last treatment for oropharynx cancer (surgery, chemotherapy, or radiation)
at least 12 months and no more than 5 years before the date of study enrollment

- Known tumor status or tumor available for HPV testing [based on chromogenic in situ
hybridization with wide spectrum HPV probe (HPV III family 16 probe (Ventana) with
affinity to HPV genotypes 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, and 66) or p16
immunohistochemistry done in a Clinical Laboratory Improvement Amendment
(CLIA)-approved laboratory; if either of these 2 tests are positive, the patient is
classified as positive].

- Able to speak and read English (study questionnaire-Aim 1 and interview guide-Aim 2
are currently only available in English).

- Received at least one component of treatment for oropharynx cancer at MSKCC or the
regional network sites

- If radiation therapy was part of treatment, it must have been delivered at MSKCC or
the regional network sites

- For Aim 2 only, diagnosed with an HPV+ oropharynx cancer and have knowledge of this
diagnosis prior to study enrollment

Exclusion Criteria:

- Diagnosed with recurrent disease following completion of primary curative treatment

We found this trial at

sites

Memorial Sloan Kettering Cancer Center

1275 York Ave
New York, New York 10021

(212) 639-2000